๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

10,225 results for โ€œHeโ€ Clear

  1. Durvalumab + SoC chemotherapy

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  2. Duvakitug, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

  3. Duvakitug, matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

  4. EADM

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  5. EB-101

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab completed

    1 trial

  6. EB-101 Surgical application of RDEB wounds

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab active

    1 trial

  7. ECULIZUMAB , ECULIZUMAB

    Pari Pharma GmbH

    Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine โ‰ฅ 354ฮผM)

    phase 3 small molecule active

    1 trial

  8. ECULIZUMAB, Crovalimab, Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  9. EFGARTIGIMOD ALFA, JNJ-80202135

    Janssen-Cilag International N.V.

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  10. EIK1001

    Eikon Therapeutics

    Non Small Cell Lung Cancer (Squamous or Non Squamous)

    phase 3 small molecule active

    1 trial

  11. EIK1001

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  12. ELECTROLYTES , DURVALUMAB, VASOPRESSIN (ARGIPRESSIN) , PREDNISOLONE , INFLIXIMAB, MYCOPHENOLATE MOFETIL, PARACETAMOL , Tarlatamab, Tarlatamab, TOCILIZUMAB, ETOPOSIDE, DEXAMETHASONE, SILTUXIMAB, CARBOPLATIN, CISPLATIN

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  13. ELECTROLYTES , VIALEBEX 200 g/L, solution pour perfusion

    Pari Pharma GmbH

    Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

    phase 3 small molecule active

    1 trial

  14. ELOXATINE 5 mg/ml, solution ร  diluer pour perfusion, ELOXATINE 5 mg/ml, solution ร  diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer and rectal with liver metastasis

    phase 3 small molecule active

    1 trial

  15. EMB-Fatolยฎ 100 mg, Tabletten, The placebo for Amikacin Liposome for Inhalation Suspension drug product is a white translucent suspension consisting of dipalmitoylphosphatidylcholine (DPPC) and cholesterol, which are dispersed in 1.5% (w/w) sodium chloride solution. The placebo is filled into the same container closure system of the drug product, Azithromycin-ratiopharm 250mg Filmtabletten, Azithromycin STADAยฎ 250 mg Filmtabletten, Azithromycin AL 250 mg Filmtabletten, Azitromicina Teva 250 mg comprimidos re

    Insmed Limited

    "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"

    phase 3 small molecule active

    1 trial

  16. EMPAGLIFLOZIN, BI 690517, Placebo matching vicadrostat

    Boehringer Ingelheim

    Heart failure

    phase 3 small molecule active

    1 trial

  17. EMPAGLIFLOZIN, Placebo matching BI 690517, BI 690517

    Boehringer Ingelheim

    Heart failure (HF)

    phase 3 small molecule active

    1 trial

  18. ENTECAVIR , VAY736, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled pen, TENOFOVIR ALAFENAMIDE , -, VAY736, TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  19. ERIBULIN MESYLATE, VINORELBINE, GEMCITABINE, CAPECITABINE, CAPECITABINE, Datopotamab deruxtecan

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  20. ETC-1002

    Esperion Therapeutics

    Hypercholesterolemia

    phase 3 small molecule completed

    6 trials

  21. ETEPLIRSEN (AVI-4658)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  22. ETOPOSIDE

    Pari Pharma GmbH

    Hemophagocytic lymphohistiocytosis (HLH)

    phase 3 small molecule active

    1 trial

  23. ETOPOSIDE , DEXAMETHASONE

    Pari Pharma GmbH

    Hemophagocytic lymphohistiocytosis (HLH)

    phase 3 small molecule active

    1 trial

  24. EV/DNG (Qlaira, BAY86-5027)

    Bayer HealthCare AG

    Oral Contraceptive

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources